Flynn James E Form SC 13G/A February 13, 2009

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
(Amendment No. 3) *
ARENA PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
040047102
(CUSIP Number)
December 31, 2008
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d)
(Page 1 of 11 Pages)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, ar for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 040047102 13G Page 2 of 1
1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Capital, L.P.

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				_ X		
3.	SEC USE	ONLY					
4.	 CITIZENS	HIP OR PLACE OF ORGANIZATION					
	Delaware						
		5. SOLE VOTING POWER					
		0					
NUMBER OF		6. SHARED VOTING POWER					
	ARES FICIALLY	2,547,304					
	ED BY ACH	7. SOLE DISPOSITIVE POWER					
	ORTING RSON	0					
W	ITH	8. SHARED DISPOSITIVE POWER					
		2,547,304					
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	2,547,30	4					
10.	CHECK BC	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN	SHARE	 [S*	_		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	3.44%						
12.	TYPE OF REPORTING PERSON*						
	PN						
CUSIP	No. 0400	47102 13G	Page	3 0:	f 11		
1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)							
	Deerfield Partners, L.P.						
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b)						
3.	SEC USE	ONLY					

4.	CITIZENS	SHIP OR PLACE OF ORGANIZATION			
	Delaware				
		5. SOLE VOTING POWER			
		0			
NUMBER OF		6. SHARED VOTING POWER			
BENE		2,547,304			
	ED BY ACH	7. SOLE DISPOSITIVE POWER			
	ORTING RSON	0			
W	ITH	8. SHARED DISPOSITIVE POWER			
		2,547,304			
9.	AGGREGAT	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	2,547,30)4			
10.	CHECK BO	DX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN	SHARES* _		
11.	PERCENT	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	3.44%				
12.	TYPE OF REPORTING PERSON*				
	PN 				
CUSIP	No. 0400	047102 13G	Page 4 of 11		
1.		REPORTING PERSONS IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	Deerfield Management Company, L.P.				
2.	CHECK TH	HE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) _ (b) X		
3.	SEC USE	ONLY			
4.		SHIP OR PLACE OF ORGANIZATION			
	New York				
		5. SOLE VOTING POWER			

SHARES BENEFICIALLY OWNED BY		0					
		6. SHARED VOTING POWER					
		4,412,544					
		7. SOLE DISPOSITIVE POWER					
PE	ORTING RSON	0					
W	ITH	8. SHARED DISPOSITIVE POWER					
		4,412,544					
9.	AGGREGAT	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	4,412,54	4					
10.	CHECK BO	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN	SHARES* _				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	5.96%						
12.	TYPE OF REPORTING PERSON*						
	PN						
CUSIP	No. 0400	47102 13G	Page 5 of 11				
1.		REPORTING PERSONS DENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)					
	Deerfiel	d International Limited					
2.	CHECK TH	E APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) _ (b) X				
3.	SEC USE	ONLY					
4.	CITIZENS	HIP OR PLACE OF ORGANIZATION					
	British	Virgin Islands 					
		5. SOLE VOTING POWER					
		0					
		6. SHARED VOTING POWER					
SHARES BENEFICIALLY OWNED BY		4,412,544					

EACH REPORTING PERSON WITH		7. SOLE DISPOSITIVE POWER 0			
		8. SHARED DISPOSITIVE POWER 4,412,544			
	A CODECAT				
	4,412,54	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
10.	CHECK BO	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN			
11.	PERCENT	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	5.96%				
12.	TYPE OF	REPORTING PERSON*			
	CO				
CUSIP	No. 0400	47102 13G	Page 6 of 11		
1.		REPORTING PERSONS DENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	James E. Flynn				
2.	CHECK TH	E APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) _ (b) X		
3.	SEC USE	ONLY			
4.	CITIZENS	HIP OR PLACE OF ORGANIZATION			
	United S	tates			
		5. SOLE VOTING POWER			
		0			
SHARES BENEFICIALLY OWNED BY EACH		6. SHARED VOTING POWER			
		6,959,848			
		7. SOLE DISPOSITIVE POWER			
PE	ORTING RSON	0			
W	ITH	8. SHARED DISPOSITIVE POWER			
		6,959,848			

9. AGGRE	EGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,959),848
10. CHECP	K BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* _
12. TYPE	OF REPORTING PERSON*
IN	
	Page 7 of 11
CUSIP No.	040047102
Item 1(a).	Name of Issuer:
	ARENA PHARMACEUTICALS, INC.
Item 1(b).	Address of Issuer's Principal Executive Offices:
	6166 Nancy Ridge Drive San Diego, California 92121
Item 2(a).	
	James E. Flynn, Deerfield Capital, L.P., Deerfield Partners, L.P., Deerfield Management Company, L.P., Deerfield International Limited,
Item 2(b).	Address of Principal Business Office, or if None, Residence:
	James E. Flynn, Deerfield Capital, L.P., Deerfield Partners, L.P. Deerfield Management Company, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017, Deerfield International Limited, c/o Bisys Management, Bison Court, Columbus Centre, P.O. Box 3460, Road Town, Tortola, British Virgin Islands
Item 2(c).	
	Mr. Flynn - United States citizen Deerfield Capital, L.P. and Deerfield Partners, L.P Delaware limited partnerships Deerfield Management Company, L.P New York limited partnership Deerfield International Limited - British Virgin Islands corporation
Item 2(d).	Title of Class of Securities:
	Common Stock
Item 2(e).	
	040047102

Item 3.			This Statement is Filed Pursuant to Rule 13d (c), Check Whether the Person Filing is a:		
(a)	[_]	Broker or dealer registered under Section 1 Act.	5 of the Exchange	
(b)	[_]	Bank as defined in Section 3(a)(6) of the E	xchange Act.	
(c)	[_]	Insurance company as defined in Section 3(a Act.)(19) of the Exchange	
(d)	[_]	Investment company registered under Section Company Act.	8 of the Investment	
(e)	[_]	An investment adviser in accordance with Ru 13d-1(b)(1)(ii)(E);	le	
(f)	[_]	An employee benefit plan or endowment fund Rule 13d-1(b)(1)(ii)(F);	in accordance with	
(g)	[_]	A parent holding company or control person Rule 13d-1(b)(1)(ii)(G);	in accordance with	
(h)	[_]	A savings association as defined in Section Deposit Insurance Act;	3(b) of the Federal	
(i)	[_]	A church plan that is excluded from the definvestment company under Section 3(c)(14) o Company Act;		
(j)	[_]	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).	
				Page 8 of 11	
Item 4.	Owr	ners	hip.		
			he following information regarding the aggre he class of securities of the issuer identif		
(a	(a) Amount beneficially owned:				
	Dee Dee Dee	Deerfield Capital, L.P 2,547,304 shares Deerfield Partners, L.P 2,547,304 shares Deerfield Management Company, L.P 4,412,544 shares Deerfield International Limited - 4,412,544 shares James E. Flynn - 6,959,848 shares			
(b) Percent of class:			t of class:		
	Deerfield Capital, L.P 3.44% Deerfield Partners, L.P 3.44% Deerfield Management Company, L.P 5.96% Deerfield International Limited - 5.96% James E. Flynn - 9.40%				
(c) Nun	nber	of shares as to which such person has:		
	(i	_)	Sole power to vote or to direct the vote	All Reporting Persons - 0	

(ii) Shared power to vote or to direct the vote

Deerfield Capital, L.P. - 2,547,304 Deerfield Partners, L.P. - 2,547,304 Deerfield Management Company, L.P. - 4,412,544 Deerfield International Limited - 4,412,544 options) James E. Flynn -6,959,848

Page 9 of 11

(iii) Sole power to dispose or to direct the disposition of

All Reporting Persons - 0

(iv) Shared power to dispose or to direct the disposition of

Deerfield Capital, L.P. - 2,547,304 Deerfield Partners, L.P. - 2,547,304 Deerfield Management Company, L.P. - 4,412,544 Deerfield International Limited - 4,412,544 James E. Flynn -6,959,848

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule,

pursuant to Rule 13d-1(b) (1) (ii) (G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A ------

Page 10 of 11

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

See Earlight B

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A ------

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

Page 11 of 11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD CAPITAL, L.P.

By: J.E. Flynn Capital LLC,

General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD PARTNERS, L.P.

By: Deerfield Capital, L.P.

By: J.E. Flynn Capital LLC,

General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD INTERNATIONAL LIMITED

By: Deerfield Management Company

By: Flynn Management LLC, General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

JAMES E. FLYNN

/s/ Darren Levine

Darren Levine, Attorney-in-Fact

Date: February 12, 2009

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C.(1) Power of Attorney.

(1) Previously field as Exhibit 24 to a Form 4 with regard to PAR Pharmaceutical Companies, Inc. field with the Commission of February 1, 2007 Deerfield Capital L.P.; Deerfield Partners, L.P.; Deerfield Management Company, L.P.; Deerfield International Limited; Deerfield Special Situations Fund, L.P.; Deerfield Special Situations Fund International Limited; and James E Flynn.

Exhibit A

Agreement

The undersigned agree that this Schedule 13G and all amendments thereto, relating to the Common Stock of ARENA PHARMACEUTICALS, INC. shall be filed on behalf of the undersigned.

DEERFIELD CAPITAL, L.P.

By: J.E. Flynn Capital LLC, General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD PARTNERS, L.P.

By: Deerfield Capital, L.P.

By: J.E. Flynn Capital LLC, General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD MANAGEMENT COMPANY

By: Flynn Management LLC General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD INTERNATIONAL LIMITED

By: Deerfield Management Company

By: Flynn Management LLC, General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

JAMES E. FLYNN

/s/ Darren Levine

Darren Levine, Attorney-in-Fact

Exhibit B

Due to the relationships between them, the reporting persons hereunder (other than Arnold H. Snider) may be deemed to constitute a "group" with one

another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.